Analysis of MLKL, RIP1 and RIP3 Immunostaining Markers in Human Liver Tissue from Fatal Yellow Fever Cases: Insights

Vanessa do Socorro Cabral Miranda1, Luiz Fabio Magno Falcão2, Hellen Thais Fuzii3

  • 1Departmento of Pathology, Evandro Chagas Institute, Ministry of Health, Ananindeua 67030-000, PA, Brazil.

Viruses
|January 25, 2025
PubMed

Insights

Necroptosis markers MLKL, RIP1, and RIP3 are significantly upregulated in the liver during fatal yellow fever (YF) infections. These necroptosis markers correlate with each other, indicating their role in YF-induced liver injury.

Area of Science:

  • Hepatology
  • Immunology
  • Pathology

Background:

  • Necroptosis, a programmed cell death pathway, is involved in viral infections and liver diseases.
  • Yellow fever (YF) is a severe viral hemorrhagic fever with significant liver pathology.

Purpose of the Study:

  • To investigate the expression and correlation of necroptosis markers (MLKL, RIP1, RIP3) in human liver tissue from fatal yellow fever cases.
  • To determine the role of necroptosis in the pathogenesis of YF-induced liver injury.

Main Methods:

  • Immunohistochemistry (IHC) was used to analyze liver tissue from 21 YF cases and 5 controls.
  • Expression levels of MLKL, RIP1, and RIP3 were quantified in different liver zones (Z3, Z2, Z1) and portal tracts (PTs).
  • Pearson correlation analysis was performed to assess the relationships among necroptosis markers.

Main Results:

  • Significantly higher expression of MLKL, RIP1, and RIP3 was observed in YF liver tissue compared to controls, particularly in zone 2.
  • Immunostaining confirmed the presence of these markers in hepatocytes and inflammatory infiltrates.
  • Significant positive correlations were found among MLKL, RIP1, and RIP3, suggesting coordinated regulation.

Conclusions:

  • Necroptosis is actively involved in the pathogenesis of yellow fever liver injury.
  • The coordinated expression of MLKL, RIP1, and RIP3 highlights their collective role in YF-induced hepatocyte death.
  • Targeting necroptosis pathways may offer therapeutic strategies for severe YF cases.